Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Juventas Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01410331
First received: July 14, 2011
Last updated: November 11, 2013
Last verified: November 2013

July 14, 2011
November 11, 2013
March 2012
July 2014   (final data collection date for primary outcome measure)
To Investigate the safety and tolerability of escalating doses of JVS-100 delivered via direct intramuscular injections to subjects with CLI. [ Time Frame: 12 Months ] [ Designated as safety issue: Yes ]
Safety assessments include tracking of AEs and SAEs and laboratory assessments
Same as current
Complete list of historical versions of study NCT01410331 on ClinicalTrials.gov Archive Site
To investigate the initial efficacy of escalating doses of JVS-100 delivered via direct intramuscular injections to subjects with CLI. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Efficacy measurements include: tracking of major/minor amputations,overall survival,Quality of Life,ulcer healing, & pressure assessments.
Same as current
Not Provided
Not Provided
 
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia
A Phase II, Randomized, Double-Blind, Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection to Cohorts of Adults With Critical Limb Ischemia

This is a double-blind, placebo controlled study designed to evaluate the safety and efficacy of JVS-100 given to adult subjects with critical limb ischemia (CLI).

48 subjects diagnosed with Rutherford Class 4-5 Critical Limb Ischemia (CLI) with non-healing ulcers and/or ischemic rest pain will be enrolled in this study designed to investigate the safety and efficacy of JVS-100. JVS-100 will be delivered by direct intramuscular injection into the limbs of study subjects. Subjects will be randomized to receive a single set of direct intramuscular injections of either JVS-100 or vehicle control and will be followed for 12 months post dosing. Safety and efficacy assessments will be collected at 3 days, 4 weeks and 3, 6 and 12 months.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Critical Limb Ischemia
  • Biological: JVS-100(4 mg) or placebo/8 injections
    4 mg of JVS-100 or placebo delivered in 8 injections
  • Biological: JVS-100(8 mg) or placebo/8 injections
    8 mg of JVS-100 or placebo delivered in 8 injections
  • Biological: JVS-100(8 mg) or placebo/16 injections
    8 mg of JVS-100 or placebo delivered in 16 injections
  • Biological: JVS-100(16 mg) or placebo/16 injections
    16 mg of JVS-100 or placebo delivered in 16 injections
  • Experimental: Cohort 1
    Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections.
    Intervention: Biological: JVS-100(4 mg) or placebo/8 injections
  • Experimental: Cohort 2
    Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections.
    Intervention: Biological: JVS-100(8 mg) or placebo/8 injections
  • Experimental: Cohort 3
    Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections.
    Intervention: Biological: JVS-100(8 mg) or placebo/16 injections
  • Experimental: Cohort 4
    Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections.
    Intervention: Biological: JVS-100(16 mg) or placebo/16 injections
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
48
August 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women 40 years of age or older
  • Rutherford Category 4 or 5
  • Ankle systolic pressure of 70mmHg or less, or toe pressure of 50mmHg or less
  • Poor option for surgical revascularization by open or endovascular strategies
  • Those diabetic subjects who are on optimal diabetes treatment, with HbA1c <8.5 %
  • Subject should be on stable therapy for the treatment of CLI, including statin and antiplatelet therapy
  • Subject must be willing to forgo treatment with hyperbaric oxygen, nerve stimulation, ot sympathectomy for treatment of CLI 10 days prior to 45 days following injection of study drug

Exclusion Criteria:

  • Life expectancy of less than 1 year
  • Previous major amputation of the leg to be treated or planned major amputation within the first month following enrollment
  • Patent revascularization (within 6 weeks)in the leg to be treated prior to enrollment
  • NYHA Class IV heart failure
  • Evidence of osteomyelitis or active infection
  • Subjects with Buerger's Disease
  • Subjects with a history of Systemic Lupus Erythematosus (SLE) flare
  • Subjects with established chronic kidney (stage 5) requiring dialysis
  • Uncontrolled blood pressure
  • Significant hepatic disease
  • Diabetic subjects with active proliferative retinopathy
  • Immunodeficient states or subjects receiving chronic immunosuppressive therapy
  • Any patient with a history of cancer unless 1)the cancer was limited to curable non-melanoma skin malignancies, or 2)the cancer was removed by successful tumor resection, with or without radiation or chemotherapy, 5 years or more prior to enrollment in this study without recurrence
  • Pregnant or lactating women or subjects of childbearing potential not protected by an effective method of birth control
  • Men unwilling to agree to barrier contraception or limit sexual activity
  • Presence of any other condition that, in the opinion of the investigator, might compromise any aspect of the trial
  • Acute coronary syndrome within 3 month prior to enrollment
  • Previous treatment with angiogenic growth factors or with stem cell therapy within 1 year
  • Participation in another clinical trial in the last 30 days
  • Clinically significant elevations in PT/PTT/INR
  • Non-heel wound size >20 cm2 (excluding toe gangrene) or heel wound size >10cm2 on the index limb
  • History of drug or alcohol abuse in the last year
Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   India
 
NCT01410331
JTCS-002
Yes
Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc.
Not Provided
Principal Investigator: Melina Kibbe, MD Northwestern University
Juventas Therapeutics, Inc.
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP